Poop pills may revive immunotherapy in lung cancer patients

NCT ID NCT07001618

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a special fecal transplant (MaaT033) alongside an immunotherapy drug (Cemiplimab) can help overcome treatment resistance in advanced lung cancer patients who have taken antibiotics. Antibiotics can harm gut bacteria, which may make immunotherapy less effective. The trial involves 162 adults and compares the combination to standard treatments chosen by their doctor. The goal is to see if the transplant can restore gut health and improve disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

CHU Grenoble
NOT_YET_RECRUITING

Grenoble, 38043, France
Centre Georges François Leclerc
NOT_YET_RECRUITING

Dijon, 21079, France
Centre Hospitalier Sainte Musse Toulon
RECRUITING

Toulon, 83000, France
Gustave Roussy
RECRUITING

Villejuif, 94800, France
Hôpital Bichat - Claude Bernard
NOT_YET_RECRUITING

Paris, 75018, France
Hôpital Foch
RECRUITING

Suresnes, 92150, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.